Product Information
BUSPIRONE HCL 5 MG TABLET is a generic product labeled by Apnar Pharma LP, priced at $0.0220 per EA under NDC 24689078101. Its NADAC has been published 213 times since Mar 3, 2021.
FDA first approved this application on May 3, 2018. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5 mg/1
Manufacturer
Apnar Pharma LPNDC
24689078101
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
BUSPIRONE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA209696FDA Approved
5/3/2018
TE Code
AB
On Market Since
6/17/2024
Price Statistics
The NADAC for BUSPIRONE HCL 5 MG TABLET has been published 213 times since Mar 3, 2021, and over the history we have for it it has declined 19.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0220 per EA |
|---|---|
| All-time high | $0.0314 (Nov 16, 2022) |
| All-time low | $0.0214 (Oct 22, 2025) |
| 52-week high | $0.0221 |
| 52-week low | $0.0214 |
| Median price | $0.0265 |
| Average price | $0.0257 |
| Largest weekly change | +11.5% (Oct 19, 2022) |
| Weeks tracked | 213 |
| Tracking since | Mar 3, 2021 |
Generic Alternatives
The matcher finds 9 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 1% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Apnar Pharma LP manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Buspirone Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BUSPIRONE HCL 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for BUSPIRONE HCL 5 MG TABLET, manufactured by Apnar Pharma LP, is $0.0220 per EA (NDC 24689078101), effective Sep 30, 2026.
How has the price of BUSPIRONE HCL 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for BUSPIRONE HCL 5 MG TABLET has declined 19.1%. It has been tracked across 213 weekly CMS publications since Mar 3, 2021.
What are the highest and lowest recorded NADAC prices for BUSPIRONE HCL 5 MG TABLET?
Since Mar 3, 2021, the NADAC for BUSPIRONE HCL 5 MG TABLET has ranged from a low of $0.0214 (Oct 22, 2025) to a high of $0.0314 (Nov 16, 2022), with a median of $0.0265 per EA.
Are there cheaper alternatives to BUSPIRONE HCL 5 MG TABLET?
Yes. 9 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, BUSPIRONE HCL 5 MG TABLET, is $0.0217 per EA — about 1% below BUSPIRONE HCL 5 MG TABLET.
Who manufactures BUSPIRONE HCL 5 MG TABLET?
BUSPIRONE HCL 5 MG TABLET (NDC 24689078101) is labeled by Apnar Pharma LP, and CMS classifies it as a generic product.